Current Illinois CancerCare Clinical Trials

A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger with High-Risk (Adverse) Acute Myeloid Leukemia

Study Number: MM1YA-S01

Study Summary:
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high-risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax.

Status: Open

Study Coordinator(s)
  • Navigator Heather, 309-243-3661
  • Hannah, 309-243-3628

Study Link

« Search Again